ReviewObesity and psoriasis: From the Medical Board of the National Psoriasis Foundation
Introduction
The association between obesity and psoriasis has been the focus of several recent reviews.1, 2, 3, 4 Obesity is defined as a body mass index (BMI) of 30 or greater, whereas morbid obesity is defined as a BMI of 35 or greater. Lindegard5 first described an association between obesity and psoriasis in a study of 159,200 registered Swedish citizens over a 10-year period. This association has been confirmed in many more recent publications.6, 7, 8, 9, 10, 11, 12, 13 In an Italian case-control study with 560 psoriatic patients, the odds of having psoriasis with a BMI between 26 and 29 or above 30 were 1.6 and 1.9, respectively, compared to non-obese control subjects.7 A study from the United Kingdom of 127,706 patients with mild psoriasis (defined as those who were not treated with systemic therapies or phototherapies) and 3,854 patients with severe psoriasis (defined as those who were treated with systemic therapies or phototherapies) demonstrated higher adjusted odds of obesity in patients with severe psoriasis (odds ratio [OR] = 1.8) than in patients with mild psoriasis (OR = 1.3) compared with patients without psoriasis.8 In a report encompassing 16,851 individuals with psoriasis, patients younger than 35 years old were more likely to demonstrate obesity (OR = 2.2) than patients older than 65 years of age (OR = 1.6) compared with normal controls.9 In another study, morbidly obese patients self-reported the presence of inverse psoriasis in 13% of cases compared to 11% of obese and 5% of non-obese patients.10 In combination, these studies suggest a positive correlation between body weight and both prevalence and severity of psoriasis.
According to National Health and Nutrition Examination Survey data, 30% of all adult U.S. citizens were obese in the 4-year period of 1999-2002.14 Given that approximately 2% of the general population has psoriasis,15 and given that psoriasis is associated with obesity, it will become increasingly important for clinicians to become familiar with appropriate treatment regimens for patients with both of these conditions. Furthermore, ongoing genetic and pathophysiologic studies offer the promise of understanding how these two common conditions are related.
Section snippets
Methods
MEDLINE and PubMed were both searched for a combination of the following terms: “obesity and psoriasis” and “metabolic syndrome and psoriasis.” Literature relevant to psoriasis and obesity or the metabolic syndrome was reviewed. Literature was additionally acquired through citations from reviews in our initial search and by searching “psoriasis” concurrently with the name of a medication or class of medications. Reports in the literature were evaluated according to the criteria of Shekelle
Obesity and psoriasis: association studies
The question of which comes first, psoriasis or obesity, is a common question. In our review of the literature, two studies provide data that psoriatic patients gain weight after the onset of psoriasis. Herron et al10 present data from 557 patients with psoriasis wherein patients were asked to recall their body size at 18 years of age (before the onset of psoriasis) and to then evaluate their current size (after the onset of psoriasis). By means of this retrospective method, self-reported
References (89)
- et al.
Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients
Atherosclerosis
(2007) - et al.
Obesity and the skin: skin physiology and skin manifestations of obesity
J Am Acad Dermatol
(2007) - et al.
Disease concomitance in psoriasis
J Am Acad Dermatol
(1995) - et al.
Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study
J Invest Dermatol
(2005) - et al.
Prevalence of cardiovascular risk factors in patients with psoriasis
J Am Acad Dermatol
(2006) - et al.
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial
J Am Acad Dermatol
(2004) - et al.
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
Lancet
(2005) - et al.
Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial
J Am Acad Dermatol
(2008) - et al.
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Lancet
(2008) - et al.
Efficacy of etanercept in an integrated multistudy database of patients with psoriasis
J Am Acad Dermatol
(2006)
Acitretin versus etretinate in psoriasis: clinical and pharmacokinetic results of a German multicenter study
J Am Acad Dermatol
Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients
Semin Arthritis Rheum
Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment
J Hepatol
Liver biopsies and methotrexate: a time for reconsideration?
J Am Acad Dermatol
Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial
Am J Clin Nutr
Psoriasis is associated with lipid abnormalities at the onset of skin disease
J Am Acad Dermatol
Additional studies on psoriasis in the tropics and in starvation camps
J Invest Dermatol
Insulin resistance: an adaptation for weight maintenance
Lancet
Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis
Clin Chim Acta
Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease
Clin Chim Acta
The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study
J Am Acad Dermatol
Lipid profile, insulin secretion, and insulin sensitivity in psoriasis
J Am Acad Dermatol
Resistin, central obesity, and type 2 diabetes
Lancet
The effect of weight on the efficacy of biologic therapy in patients with psoriasis
J Am Acad Dermatol
AJC editor's consensus: psoriasis and coronary artery disease
Am J Cardiol
Methotrexate guidelines—revised
J Am Acad Dermatol
Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis
Pharmacol Res
Effect of anti TNF-alpha therapy on arterial diameter and wall shear stress and HDL cholesterol
Atherosclerosis
Metabolic disorders in patients with psoriasis and psoriatic arthritis
Curr Rheumatol Res
Obesity in psoriasis: The metabolic, clinical and therapeutic implications. report of an interdisciplinary conference and review
Br J Dermatol
Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes
Dermatologica
Association between psoriasis and the metabolic syndrome. A cross-sectional study
Dermatology
Impact of obesity and smoking on psoriasis presentation and management
Arch Dermatol
Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis
Arch Dermatol Res
Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome
Arch Dermatol
Relationship of psoriasis to obesity using same-gender siblings as controls for obesity
Clin Exp Dermatol
The prevalence of psoriasis in the world
J Eur Acad Dermatol Venereol
Clinical guidelines: developing guidelines
BMJ
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis
J Am Acad Dermatol
Consistency of infliximab response across subgroups of patients with psoriasis: integrated results from randomized clinical trials
J Am Acad Dermatol
Levels of response of psoriasis patients with different baseline characteristics treated with etanercept
J Am Acad Dermatol
Safety and efficacy of alefacept in elderly patients and other special populations
J Drugs Dermatol
Cited by (96)
Change in body weight and body mass index in psoriasis patients receiving biologics: A systematic review and network meta-analysis
2020, Journal of the American Academy of DermatologyHigh-Fat Diet Exacerbates Early Psoriatic Skin Inflammation Independent of Obesity: Saturated Fatty Acids as Key Players
2018, Journal of Investigative DermatologyModeling clinical efficacy of the S1P receptor modulator ponesimod in psoriasis
2018, Journal of Dermatological ScienceA crossroads between dietary habits, alcohol consumption, and smoking in the clinical course of psoriasis: a narrative review
2023, Postepy Dermatologii i Alergologii
Funded by the National Psoriasis Foundation, Portland, OR.
Disclosures: Dr Bremmer has no disclosures to report. Dr Van Voorhees has been a consultant, investigator, or speaker for Abbott, Amgen, Astellas, Centocor, Genentech, Incyte, Connetics, Warner Chilcott, Photomedix, Roche, and Synta; she also has a significant conflict of interest with Merck. Dr Hsu has been a consultant for Abbott, Amgen, Biogen Idec, Centocor, and Genentech; she has been a clinical investigator for Amgen and Centocor. Dr Korman has been an investigator or speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Dr Lebwohl has been a consultant for Abbott, Amgen, Astellas, Centocor, Genentech, UCB Pharma, Stiefel, Triax, Pharmaderm, Medicis, Novartis, and Warner Chilcott; he has been a speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Ms Young has been a consultant or speaker for Abbott, Amgen, Astellas, Biogen Idec, Centocor, and Genentech. Dr Bebo is employed by the National Psoriasis Foundation. The Foundation receives unrestricted financial support from Abbott, Centocor, Amgen, Wyeth, Genentech, Astellas, Stiefel, Galderma, Warner Chilcott, and Photomedix. Dr Blauvelt has been a consultant, investigator, or speaker for Abbott, Amgen, Centocor, Genentech, Anacor, Coria, Vascular Biogenics, PM Toleikis & Associates, MacroGenics, Eli Lilly, CombinatoRx, Cerimon, Barrier Therapeutics, Pfizer, and Novo Nordisk.